Pharma seeks patent and other intellectual property
rights to protect and preserve our proprietary
technology and our right to capitalize on the
results of our research and development activities.
We also rely on trade secrets, know-how, continuing
technological innovations and licensing opportunities
to prove competitive advantages for our products
in our markets and to develop new products.
Nutra Pharma holds a license to certain intellectual
property from Bio Therapeutics, which it intends
to utilize in conjunction with Receptopharm's
research and development of modified venom and
peptides thereof in applications for the treatment
of HIV and MS.
- U.S. Patent No. 5,989,857, which was granted
in November 1999 with 10 claims.
- U.S. Patent No. 6,670,148, which was granted
in December 2003, with 9 claims. The patent
further describes the method for preparing a
bioactive peptide (protein) found in cobra venom,
in a stable, inactivated form, by treating the
peptide with ozone.
- Buccal Delivery System, on which a patent
is pending. This application describes a throat
spray that permits efficient delivery of the
modified peptide drugs to the body through oral
- Technology contained in one pending U.S. patent
application for the further development of bioactive
peptides in cobra venom for use in the treatment
of HIV and MS.
- Technology contained in two pending U.S. patent
applications for Immunokine Composition and
Method, which describes a method for developing
modified peptides from alpha-cobratoxin.
- Technology contained in two patents pending
for the topical delivery of our proprietary
wound healing treatment, which was developed
in conjunction with Bio Therapeutics. One of
these products is in the form of an ointment
style skin protectant and the other a foaming